filmov
tv
Estatina: solução ou enganação?
Показать описание
Estatina faz bem ou faz mal? Dr. Pedro Duccini explica a polêmica com base em evidências científicas.
Dr. Pedro Duccini - CRM: 121.561 - SP / RQE: 52 175
E para quem duvida, seguem algumas das principais referencias científicas sobre o assunto:
1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials - Lancet 2010; 376: 1670–81
2. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.
3. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
4. Statin-Associated Side Effects. J Am Coll Cardiol 2016.
5. Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol 2017; 109(2Supl.1):1-76
6. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9494):1358; Lancet. 2008;371(9630):2084.
7. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline. Ann Intern Med. 2014;160(5):339-43.
8. Statins and Cognitive Function: A Systematic Review. Richardson K et al. Ann Intern Med. 2013;159(10):688-697
9. Statin-Associated Side Effects. J Am Coll Cardiol 2016.
10. Reduzir o colesterol LDL diminui risco cardiovascular, mas o "como" importa, mostra meta-análise - Medscape - 25 de outubro de 2016
11. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;389(10088):2473–81.
Dr. Pedro Duccini - CRM: 121.561 - SP / RQE: 52 175
E para quem duvida, seguem algumas das principais referencias científicas sobre o assunto:
1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials - Lancet 2010; 376: 1670–81
2. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006; 368: 1155–63.
3. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195–207.
4. Statin-Associated Side Effects. J Am Coll Cardiol 2016.
5. Faludi AA, Izar MCO, Saraiva JFK, Chacra APM, Bianco HT, Afiune Neto A et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017. Arq Bras Cardiol 2017; 109(2Supl.1):1-76
6. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9494):1358; Lancet. 2008;371(9630):2084.
7. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline. Ann Intern Med. 2014;160(5):339-43.
8. Statins and Cognitive Function: A Systematic Review. Richardson K et al. Ann Intern Med. 2013;159(10):688-697
9. Statin-Associated Side Effects. J Am Coll Cardiol 2016.
10. Reduzir o colesterol LDL diminui risco cardiovascular, mas o "como" importa, mostra meta-análise - Medscape - 25 de outubro de 2016
11. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 2017;389(10088):2473–81.
Комментарии